Alume Appoints Daniel Bradbury as Exec. Chair; Welcomes Drs. Geoffrey Ling & Craig Venter to Advisory Board

Appointments advance fluorescence from Nobel discovery to Precision Surgery®

Published on Feb. 17, 2026

Got story updates? Submit your updates here. ›

Alume Biosciences, a clinical-stage biotech company advancing precision imaging agents for surgery, has appointed Daniel M. Bradbury as Executive Chair of its Board of Directors. The company also announced the appointments of Drs. Geoffrey Ling and Craig Venter to its Strategic Advisory Board, further strengthening its scientific and translational leadership.

Why it matters

Alume's platform represents the clinical evolution of fluorescence science, extending the legacy of Nobel Laureate Dr. Roger Y. Tsien's pioneering work in fluorescent proteins beyond the lab and into the operating room as a precision surgical technology.

The details

As Executive Chair, Bradbury will guide Alume through its next phase of regulatory advancement, strategic growth, and commercialization. Drs. Ling and Venter bring unparalleled expertise in translating breakthrough technologies into operational practice and scaling transformative platforms that redefine fields of medicine.

  • Alume announced the appointments on February 16, 2026.

The players

Daniel M. Bradbury

An experienced biotechnology executive who has served as President and CEO of Amylin Pharmaceuticals and currently serves as Chairman of Castle Biosciences, Equillium, and Vivani Medical.

Dr. Geoffrey Ling

A retired U.S. Army Colonel, neurocritical care physician at Johns Hopkins, and founding director of DARPA's Biological Technologies Office, with expertise in moving medical breakthroughs from concept to high-stakes clinical application.

Dr. Craig Venter

A pioneering genomic scientist and entrepreneur, celebrated for leading the first sequence of the human genome and creating the first synthetic bacterial cell, with experience scaling transformative platforms.

Dr. Quyen Nguyen

The Founder and CEO of Alume Biosciences, who is carrying forward the vision of the late Nobel Laureate Dr. Roger Y. Tsien to translate fluorescence from a discovery platform into a clinical tool that helps surgeons operate with greater precision.

Got photos? Submit your photos here. ›

What they’re saying

“Alume exemplifies the full arc of innovation beginning with Nobel Prize–winning discovery science and advancing through disciplined translational development.”

— Daniel M. Bradbury, Executive Chair, Alume Biosciences

“Roger believed deeply that his scientific efforts should ultimately serve patients. Our mission is to carry that vision forward, to translate fluorescence from a discovery platform into a clinical tool that helps surgeons operate with greater precision.”

— Dr. Quyen Nguyen, Founder and CEO, Alume Biosciences

What’s next

Alume is expected to continue advancing its fluorescence-based precision imaging agents through regulatory milestones and towards commercialization, with the guidance of its newly appointed Executive Chair and Strategic Advisory Board members.

The takeaway

Alume's appointments of seasoned biotechnology leaders and renowned scientific experts demonstrate the company's commitment to translating Nobel-winning discoveries into real-world clinical solutions that can improve surgical precision and patient outcomes.